FDA Warning Letter 695607-12102024: Summit Research Peptides
Updated August 21, 2026
Summit Research Peptides received FDA warning letter 695607-12102024, issued December 10, 2024 as part of a four-letter batch to research-peptide sellers. The letter identified five compounds and cited, alongside the product catalog, a Facebook post from the company's account that carried therapeutic-outcome claims for a compound pairing.
Letter record
| Recipient | Summit Research Peptides |
|---|---|
| Letter number | 695607-12102024 |
| Letter date | December 10, 2024 |
| Batch | One of four warning letters issued to research-peptide sellers on the same date |
| Response window | 15 working days |
| Agency position | Products identified as unapproved new drugs on the evidence of intended use FDA assembled |
| Labeling at issue | Products marketed as "research use only"; FDA cited website and social-media evidence of intended human use |
Compounds identified in the letter
The letter names the following products. Each entry below is transcribed from the letter without commentary.
| # | Compound, as named in the letter |
|---|---|
| 1 | Semaglutide |
| 2 | Retatrutide |
| 3 | Cagrilintide |
| 4 | Tirzepatide |
| 5 | Mazdutide |
Evidence cited beyond the product catalog
In addition to the website's own listings, the letter cited a post from the company's Facebook account. This index describes that post only abstractly: it carried therapeutic-outcome claims for a two-compound pairing drawn from the catalog. FDA placed the post in the same evidentiary category as the listings themselves — material bearing on the products' intended use.
The December 10, 2024 batch
| Entity | Letter number | Index record |
|---|---|---|
| Summit Research Peptides | 695607-12102024 | This page |
| Prime Vitality Inc dba Prime Peptides | 695156-12102024 | Prime Peptides letter |
| Xcel Research LLC | 694608-12102024 | Xcel Research letter |
| SwissChems | Same batch; number not captured by this index | SwissChems letter |
The four letters share a profile: each recipient marketed GLP-1-class compounds as "research use only," and in each case FDA found evidence on the seller's website or social media that the products were intended for human use. Each letter allowed 15 working days to respond. Secondary coverage of the batch appeared in the FDA Roundup of December 17, 2024, and in trade and legal press.
Reference note: a seller's public footprint is one evidentiary record
What the Summit Research Peptides letter documents, beyond its own facts, is how an intended-use case is assembled. The agency did not confine its review to the storefront: the website, the catalog, and the company's social accounts were weighed together, and a citation drawn from a social platform sat beside citations drawn from product pages. A research-use disclaimer in one location does not partition that record; material published anywhere under a seller's name can be counted against its labeling. The seven letters signed on March 31, 2026 extend the same aggregate reading to shopping-cart contents and coded product names.
Summit Research Peptides is one entry in this index's vendor record of 2024–2026 enforcement actions and closures.
Sources
- FDA Warning Letter, Summit Research Peptides, 695607-12102024. fda.gov
- FDA Warning Letters index (December 10, 2024 batch, including the SwissChems letter). fda.gov
- FDA Roundup, December 17, 2024. fda.gov
Further reading
- Summit Research Peptides alternative: successor-audit criteria — Artemis Labs store article on the same letter.
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.